-+ 0.00%
-+ 0.00%
-+ 0.00%

Haite Biotech (300683.SZ): Epneamin for injection received drug clinical trial approval

Zhitongcaijing·09/28/2026 09:33:17
Listen to the news

Zhitong Finance App News, Haite Biotech (300683.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” (Notice Number: 2026LP02967) approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). The company's declared clinical trial application for injectable epnamine (trade name: SAT) has been approved by the State Drug Administration, agreeing to carry out clinical trials on chondrosarcoma.